Zai Lab Ltd (ZLAB.OQ) saw its shares plummet 5.21% in pre-market trading on Friday after the biopharmaceutical company reported a wider-than-expected loss for the fourth quarter and revenue that fell slightly short of Wall Street estimates.
The company reported an adjusted loss of $0.80 per share for the quarter ended December 31, higher than the analyst consensus estimate of a $0.65 loss per share. Revenue rose 64.8% year-over-year to $108.51 million, but missed analysts' expectation of $110.21 million.
Despite the disappointing quarterly results, analysts remain optimistic about Zai Lab's prospects, with 12 out of 12 analysts rating the stock as a "buy" or "strong buy." The average consensus price target for the stock stands at $50.00, representing significant upside potential from its current levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.